Tandem t:slim X2 pump cleared for use with Lilly’s Lyumjev ultra-rapid insulin

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received approval to deliver Lyumjev ultra-rapid acting insulin with its t:slim X2 pump.

Eli Lilly offers the Lyumjev (insulin lispro-aabc injection) ultra-rapid acting insulin. Tandem can now provide its t:slim X2 pump with Control-IQ+ automated insulin delivery technology with the insulin in the U.S.

This latest clearance means t:slim X2 can deliver Humalog, Novolog and Lyumjev U-100 insulins in the U.S.

San Diego-based Tandem — one of the largest diabetes tech companies in the world — said it supported Lyumjev clearance for its pump with data from a 13-week, multi-center study of 179 individuals. Outcomes demonstrated high satisfaction and quality of life benefits.

Sign up for Blog Updates